Vertigo is a symptom encountered very commonly in clinical practice due to a disorder in the vestibular system. In addition to dizziness it is very often accompanied by nausea and vomiting. Pharmacotherapy plays an important role in the management of vertigo. Vestibular suppressants and drugs to control nausea and vomiting constitute the mainstay of the pharmacotherapy of vertigo. Specific drug therapy can be given in patients where the underlying disease process causing the vertigo has been identified. Despite the availability of many classes of drugs, there are no definitive, universally accepted guidelines for the treatment of vertigo which makes it even more difficult to follow first-, second-and third-line therapies when treating patients. It is difficult to establish guidelines or a generally acceptable consensus in the treatment of vertigo due to the complexity of vertigo and lack of adequate randomized clinical studies.
INTRODUCTION
The enigma and difficulty in the treatment for vertigo is due to the fact that it is not a definite disease but a symptom. Vertigo usually occurs due to a disturbance in the vestibular system.
Depending on their etiology though, vestibular diseases can be treated with drugs, physical therapy, psychotherapeutic measures and rarely surgery. Pharmacotherapy plays a crucial role in the management of vertigo. Till date it has been only possible to treat vertigo as a symptom and not a disease. Understanding pathophysiology plays an important role since it helps in deciding appropriate pharmacotherapy.
The vestibular system includes end organs which are the bony labyrinths of the inner ear consisting of three semicircular canals, the utricle and saccule (otolithic apparatus) on each side. The angular and the linear acceleration produced in the semicircular canals and otolithic apparatus gives an individual a sense of head position in space. The neural output of these end organs is conveyed to the vestibular nucleus in the brain stem via the eight cranial nerve. 1 The neural projections further to the III, IV and VI cranial nerves as well as spinal cord, cerebral cortex and cerebellum provide conscious awareness of head position and movement. 1 The vestibular system is one of the three sensory components helping an individual to attain spatial orientation and posture; whereas the other two being the visual and somatosensory systems.
The neurotransmitters required to be manipulated are the ones involved in vestibular transmission namely which are released in the cholinergic, monoaminergic and glutamatergic synapses and involved in central and peripheral vestibular circuits. There are several neurotransmitters which influence the 'three neuron arc' between the vestibular hair cells and oculomotor nuclei that drives the vestibulocular reflex. 2 Glutamate is the major excitatory neurotransmitter acting through the N-methyl-D-aspartate (NMDA) receptors in the vestibular nerve fibers. [3] [4] [5] M2 cholinergic receptors are involved with dizziness. 6 Gamma-aminobutyric acid (GABA) an inhibitory neurotransmitter is found in the vestibular neurons leading to stimulation of GABA-A and GABA-B receptors. 7 Histamine acts on H1 and H2 receptors present pre-and postsynaptically on vestibular cells and affects vestibular response. Dopamine and noradrenaline also modulate the intensity of reactions to the vestibular system. 8, 9 Adrenocorticotropic hormone (ACTH) has been reported to accelerate vestibular compensation. 10 This below article focuses exclusively on the pharmacotherapy of vertigo which is due to a disturbance in the vestibular system; excluding the other causes like motion sickness and orthostatic hypotension.
Pharmacotherapy of Vertigo
There is a paucity of information on the drug treatment of vertigo even today, since there have been no multicentric, well controlled clinical studies to demonstrate the advantage of treatment over no treatment. 11 In patients suffering from migraine, epilepsy or Meniere's disease where the cause of the vertigo is known specific drug treatment is possible. But this scenario is very rare keeping in mind the number of patients suffering from vertigo.
Vestibular suppressants are the mainstay of treatment in patients suffering from vertigo today. These drugs reduce the asymmetry in the vestibular tone between the ears and thereby reduce vertigo. 1 They include anticholinergics, antihistaminics, antidopaminergic drugs and benzodiazepines.
Anticholinergics: They act on muscarinic receptors and increase motion tolerance. Only centrally acting anticholinergics are useful in treating vertigo. Scopalamine is one of the most effective singly acting agent to prevent vertigo by acting on the M3 and M5 receptors. 8 These drugs have prominent side effects like dry mouth, dilated pupils, sedation, decreased alertness and impaired attention. Prolonged use of scopolamine as a transdermal patch may also lead to chemical addiction. 12 Anticholinergics selective for vestibular subtypes of muscarinic receptors are being developed, one such being zamifenacin. 13, 14 Antihistaminics: The H1 blockers are currently the most commonly prescribed drugs for vertigo which include; diphenhydramine, cyclizine, dimenhydrinate, meclizine and promethazine. 15, 16 This is the only class of drugs being quoted as having antivertigo properties. 17 Meclizine is the only long-acting drug among the antihistaminics used. They have lesser side effects in comparision with anticholinergics. Some antihistaminics have side effects similar to anticholinergics, since the antivertigo effect is due to their anticholinergic property. 8 Cinnarizine: It plays an important role in the treatment of vertigo by blocking the entry of calcium into the plasmamembranes especially after adrenergic stimulation. 18 The basic action of this drug is acting as a labrynthine sedative. 19 Histaminergic medications: This class of drugs is represented by betahistine which is an analogue of L-histidine, the immediate precursor of histamine. The antivertigo effects of betahistine are sometimes explained as a vasodilatory effect, improving blood flow in the microcirculation of the internal auditory and vestibular systems. 20, 21 It has a complex effect on histamine receptors, being both a partial H1 postsynaptic agonist causing vasodilation and H3 presynaptic antagonist increasing histamine secretion, leading to final facilitation of histaminergic neurotransmission. 22, 23 This improves neuronal electrical activity in the vestibular nuclei. 24 Dopaminergic antagonists: These drugs are commonly used to control nausea in vertiginous patients. Several antipsychotics namely phenothiazine derivatives and butyrophenones are popular in this condition. 25 Neuroleptics exert an antiemetic effect by blocking the dopaminergic receptors in the area postrema of the brain stem. They reduce the neurovegetative symptoms that commonly parallel vertigo and may improve the psychoaffective symptoms accompanying vertigo. These drugs are not known to exert specific dopaminergic vestibular effects but do possess anticholinergic and antihistaminic (H1) properties that explains a vestibular suppressant activity. 2 Drugs like metoclopramide which is a dopaminergic antagonist as well as serotenergic antagonist speeds up gatric emptying and has a central antiemetic effect by acting on the chemoreceptor trigger zone in the medulla oblongata. The side effects of these drugs are sedation, dry mouth and extrapyramidal symptoms.
The newer 5HT3 antagonists like ondansetron, tropisetron and granisetron inhibit the afferent vagal impulses and the vomiting center in the medulla oblongata are used as drugs of choice in cancer chemotherapy, radiotherapy and surgery or anesthesia induced vomiting. These drugs seldom play a role in controlling nausea and vomiting in vertigo. 26 Some H1 antihistaminics like promethazine also block dopamine receptors, and hence, useful in vertigo. 14 Benzodiazepines (BZDs): They act as vestibular suppressants through the GABA ergic system. GABA is an inhibitory neurotransmitter of the vertibular system. BZDs enhance the role of GABA in the central nervous system and effective in relieving vertigo and associated anxiety and panic disorders. 27, 28 They also cause muscle relaxation, anterograde amnesia and have muscle relaxant property.
The most often prescribed BZDs are diazepam, lorazepam, clonazepam and alprazolam. 27, 28 Calcium antagonists: Cinnarizine which features as a antihistaminic above and flunarizine have been used as antivertigo drugs. 29, 30 Both these drugs prevent motion sickness and are vestibular depressants since the vestibular hair cells have calcium channels. 31, 32 It is postulated that calcium channel blockers inhibit the flow of calcium from the endolymph to the cells of the crista ampullaris which is required for trigerring an action potential that is propagated centrally. 33 They also have anticholinergic, antihistaminergic and antidopaminergic actions. 34 Another calcium channel blocker nimodipine was shown to be effective in Meniere's disease. 35 Anticonvulsants: Gabapentin, carbamazepine and oxcarbazepine are used in the treatment of vertigo although not studied extensively. They are preferred for the treatment of nystagmus. 36 Another GABA agonist, baclofen has been tried for vertigo by reducing vestibular asymmetry; though no human trials have been undertaken. 37 Sympathomimetics: Sympathomimetic drugs enhance vigilance and counterbalance the sedative effects of other antivertigo drugs like antihistaminics. 14 The addictive potential of amphetamines makes the use of these drugs rare. Miscellaneous agents: Apart from the drugs mentioned above, there are many other drugs which have shown beneficial effects in the treatment of vertigo. However, it is interesting to note that many drugs have not yet been approved by regulators in many countries since they lack randomized clinical studies proving their efficacy against vertigo. Evidence available for these drugs comes from anecdotal data, case reports, review articles or clinical studies conducted with little number of patients. Acetylleucine was aggressively marketed in France for vertigo. [38] [39] [40] It may act as a precursor of a peptidic neuromediator responsible for activation of vestibular afferents. It may also have 'anticalcium' properties on neurotransmission. Oral and intravenous formulations are available.
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Piribedil is an dopaminergic agonist used as an antivertigo agent. 41 Vertigo is an example where both agonists and antagonists have shown to produce symptomatic relief owing to the complexity of the condition.
Piracetam is a nootropic drug that is a cyclic derivative of GABA. It alleviates vertigo after a head injury or vertigo of central origin, especially in vertebrobasilar insufficiency. It only decreses the frequency and not the severity of exacerbations in patients with chronic or recurrent vertigo. 42 Ginko biloba causes increase in microcirculation and also possess antioxidant properties. Some studies have showed an equal efficacy of ginko biloba and betahistine in the treatment of vertigo. 43 Bromocriptine may speed vestibular compensation and hence tried as an antivertigo drug. 44 Trimetazidine, which is a selective inhibitor of 3 ketoacyl CoA thiolase enzyme used in angina has been tried for vertigo. [45] [46] [47] Droperidol and fentanyl : Though it has no beneficial effect in chronic vertigo, a combination of droperidol and fentanyl has been tried for acute peripheral vertigo. 48 Diuretics: Hydrochlorothiazide has been known to improve vertigo due to Meniere's disease by decreasing the intralabyrinthine fluid pressure. 49, 50 Despite presence of the drugs mentioned above and summarized in the table (Table 1) , there are still lot of questioned which need to be answered. Drug dosage, duration, combination therapy, drug interactions, use of drugs as primary agents and in refractory cases are some of these questions which need to be scientifically answered by designing well-planned clinical studies.
CONCLUSION
There is a high incidence of patients presenting to the otorhinolaryngology clinics with vertigo. Depending on whether the patient is suffering from acute vertigo or chronic vertigo, the clinician has to use his expertise to select specific drugs for optimum patient benefit. It needs to be stressed that the cure for vertigo is not permanent, unless the underlying disease process is identified. Thus, the duration of therapy for vertigo can only last for a few days. This article outlines many targets and drugs available for the treatment in vertigo. However, it is important to note that many drugs do not have adequately powered, randomized clinical studies proving their efficacy in vertigo and many drugs are not approved for the use in vertigo. This definitely highlights the need to have well-defined clinical studies and newer drugs which would address unanswered questions and unmet needs experienced in the treatment of vertigo.
